Clinical Trials Sponsored by Artielle ImmunoTherapeutics

Total 50 results

Artielle ImmunoTherapeutics

Unknown

Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis

Multiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting

United States
OSE Immunotherapeutics

Recruiting

To Evaluate the Safety, and Immunogenicity of Vaccine Candidate Against COVID-19, in Healthy Adults (COVEPIT 3)

Coronavirus Disease (COVID-19)

Belgium
Avant Immunotherapeutics

Completed

Safety and Efficacy of TP10, a Complement Inhibitor, in Adult Women Undergoing Cardiopulmonary Bypass Surgery

Myocardial Ischemia | Mitral Valve Insufficiency | Aortic Valve Insufficiency | Coronary Arteriosclerosis

United States
Alladapt Immunotherapeutics, Inc.

Terminated

Open-label Extension Study of ADP101

Food Allergy

United States
Alladapt Immunotherapeutics, Inc.

Completed

ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults

Food Allergy

United States
OSE Immunotherapeutics

Recruiting

Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas

Lymphoma | Solid Advanced Tumor

France, Belgium
OSE Immunotherapeutics

Recruiting

Study of OSE-127 vs Placebo in Patients With Moderate to Severe Active Ulcerative Colitis (CoTikiS)

Ulcerative Colitis

Belgium, Latvia, Bulgaria, Belarus, Croatia, Georgia, Hungary, Poland, Russian Federation, South Africa, Ukraine
OSE Immunotherapeutics

Terminated

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure (ATALANTE-1)

Non Small Cell Lung Cancer

France, Spain, Israel, United States, United Kingdom, Italy, Poland, Czechia, Germany, Hungary
OSE Immunotherapeutics

Completed

Safety, Tolerability, PK, PD, and Immunogenicity of Single and Multiple Ascending Intravenous Doses of FR104

Rheumatoid Arthritis | Complication of Transplant

Belgium
Avant Immunotherapeutics

Completed

Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects

Typhoid Fever

United States
SIRPant Immunotherapeutics, Inc.

Recruiting

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

Refractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin Lymphoma

United States
Elixiron Immunotherapeutics Inc.

Recruiting

First in Human Study of EI-001 Monoclonal Antibody in Healthy Volunteers

Healthy

Australia
Brooklyn ImmunoTherapeutics, LLC

Completed

IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity (INSPIRE)

Squamous Cell Carcinoma of the Oral Cavity

United States, Brazil, United Kingdom, Canada
Heidelberg ImmunoTherapeutics GmbH

Terminated

Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 1 Infection (MATCH-1)

Herpes Labialis

Germany
RUTI Immunotherapeutics S.L.

Completed

Exploratory Study to Evaluate the Efficacy of RUTI® Against SARS-COV-2 Infection (COVID-19) in Healthcare Workers

Covid-19

Argentina
OSE Immunotherapeutics
Servier

Completed

Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of OSE-127 in Healthy Subjects

Healthy Subjects

Belgium
Innate Immunotherapeutics
Syneos Health

Completed

Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis

Secondary Progressive Multiple Sclerosis

New Zealand, Australia
MoonLake Immunotherapeutics AG

Active, not recruiting

Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

Arthritis, Psoriatic

United States, Spain, Bulgaria, Poland, Czechia, Estonia, Germany, Hungary
MoonLake Immunotherapeutics AG

Completed

Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa

Germany, United States, Bulgaria, Canada, Ireland, Netherlands, Poland
Heidelberg ImmunoTherapeutics GmbH

Completed

Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 2 Infection (MATCH-2)

Herpes Genitalis

Germany
Brooklyn ImmunoTherapeutics, LLC

Completed

A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck
Elixiron Immunotherapeutics Inc.
Parexel

Completed

A Study to Evaluate the Safety, Tolerability and Amount of EI-1071 in Blood in Healthy Volunteers

Healthy Volunteers

United States
OSE Immunotherapeutics
Boehringer Ingelheim

Active, not recruiting

A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours

Solid Tumor, Adult

France, Belgium
Nantes University Hospital
OSE Immunotherapeutics

Active, not recruiting

Phase I/II Study of FR104 First Administration In Patient With Renal Transplantation: FIRsT Study (FIRsT)

Kidney Transplantation

France
GERCOR - Multidisciplinary Oncology Cooperative...
OSE Immunotherapeutics

Recruiting

Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (TEDOPAM)

Metastatic Cancer | Pancreatic Ductal Adenocarcinoma | Locally Advanced Cancer

France
AIDS Healthcare Foundation
HIV Immunotherapeutics Institute

Completed

Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection

HIV-1-infection | Gut Inflammation

United States
Providence Health & Services
Brooklyn ImmunoTherapeutics, LLC

Active, not recruiting

Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)

Breast Neoplasm | Triple Negative Breast Cancer | Breast Neoplasm, Male

United States
Emory University
Bristol-Myers Squibb; Brooklyn ImmunoTherapeutics, LLC

Withdrawn

Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer

Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma | Stage II Oral Cavity Squamous Cell...

United States
Innate Immunotherapeutics
National Multiple Sclerosis Society; Primorus Clinical Trials

Completed

Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis

Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

New Zealand
Ariella Shitrit

Unknown

The Safety Assessment of Vedolizumab During Pregnancy in IBD Patient

Pregnancy Complications

Israel
ARCAGY/ GINECO GROUP
Merck Sharp & Dohme LLC; OSE Immunotherapeutics

Recruiting

OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC (TEDOVA)

Relapsed Ovarian Cancer | Platinum-sensitive Ovarian Cancer

Belgium, France, Germany
University of Southern California
National Cancer Institute (NCI); Brooklyn ImmunoTherapeutics, LLC

Active, not recruiting

IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3

Cervical Squamous Cell Carcinoma In Situ | Vulvar High Grade Squamous Intraepithelial Lesion

United States
PT. Innovative Pharma Solutions
Archivel Farma S.L.; RUTI Immunotherapeutics S.L.

Withdrawn

A Clinical Trial to Evaluate the Efficacy of RUTI® to Reduce the Severity of SARS-CoV-2 Infection (COVID-19)

COVID-19
Providence Health & Services
Merck Sharp & Dohme LLC; Brooklyn ImmunoTherapeutics, LLC

Active, not recruiting

Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer

Breast Cancer | Breast Neoplasms

United States
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca; Brooklyn ImmunoTherapeutics, LLC

Active, not recruiting

IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma

Squamous Cell Carcinoma of the Head and Neck | Oropharynx Squamous Cell Carcinoma | Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma | Metastatic Squamous Cell Carcinoma | Hypopharynx Squamous Cell Carcinoma | Paranasal Sinus Squamous Cell Carcinoma | Larynx Squamous Cell Carcinoma

United States
University Hospital, Grenoble
Fondation de Recherche sur l'Hypertension Artérielle

Completed

Study of the Relationships Between Refractory Hypertension, Overweight/Obesity and Sleep Apnea Syndrome (RHOOSAS)

Refractory Hypertension

France
Daniel Landi
Pediatric Brain Tumor Foundation; Annias Immunotherapeutics, Inc.

Active, not recruiting

PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma (PRiME)

Malignant Glioma | Recurrent Medulloblastoma | Recurrent Brain Tumor, Childhood

United States
Assistance Publique - Hôpitaux de Paris
Société Française d'Hypentension Artérielle

Active, not recruiting

Monochorial-diamniotic Pregnancies Complicated With a Twin-to-twin Syndrome (STT)

Twin to Twin Transfusion Syndrome

France
Assistance Publique - Hôpitaux de Paris
Fondation de Recherche sur l'Hypertension Artérielle

Completed

Cross-sectional Study of Patients With Renal or Craniocervical Fibromuscular Dysplasia (ARCADIA)

Fibromuscular Dysplasia

France, Belgium
Robert Wood Johnson Barnabas Health
Brielle Orthopedics; University Orthopedics Associates

Not yet recruiting

Efficacy of Steroids on Functional Outcomes After Musculoskeletal Injuries of the Hand

Finger Injuries | Hand Injuries

United States
Nova Immunotherapeutics Limited
The Emmes Company, LLC; Nova Laboratories Limited; Mercia Pharma Inc.

Unknown

The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101) (MER4101)

Influenza, Human

United States
Robert Wood Johnson Barnabas Health
Brielle Orthopedics; Universtiy Orthopedics Associates

Recruiting

Early Mobilization Following Volar Locking Plate Fixation of Distal Radius Fractures

Distal Radius Fracture

United States
Assistance Publique - Hôpitaux de Paris
Fondation de Recherche sur l'Hypertension Artérielle

Completed

Cohort Follow-up of Patients With Renal or Craniocervical Fibromuscular Dysplasia (PROFILE)

Fibromuscular Dysplasia

France, Belgium
OneChain Immunotherapeutics
Hospital Clinic of Barcelona; Hospital Sant Joan de Deu; BioClever 2005 S.L.

Recruiting

Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL (CARxALL)

T-cell Acute Lymphoblastic Leukemia | Lymphoblastic T-Cell Lymphoma

Spain
Institute of Cardiometabolism and Nutrition, France
Fondation de Recherche sur l'Hypertension Artérielle

Unknown

Retina Microvascular Remodeling and Cognitive Function In Hypertension (EYEBRAIN)

Hypertension | Mild Cognitive Impairment

France
University of Colorado, Denver
The Leona M. and Harry B. Helmsley Charitable Trust; Nova Immunotherapeutics...

Recruiting

MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes (MER3101)

Type 1 Diabetes Mellitus

United States
Eric Thompson, M.D.
National Cancer Institute (NCI); National Institutes of Health (NIH); Annias...

Terminated

Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens (PERFORMANCE)

Glioblastoma | Glioblastoma Multiforme

United States
Assistance Publique - Hôpitaux de Paris
Ministry of Health, France; Fondation pour la Recherche en Hypertension Artérielle

Unknown

Strategy for Preventing Cardiovascular and Renal Events Based on ARTErial Stiffness (SPARTE)

Hypertension

France
International Vaccine Institute
International Centre for Diarrhoeal Disease Research, Bangladesh; Christian... and other collaborators

Terminated

Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi Infants

Diarrhea | Cholera | Vibrio Infections

Bangladesh, India
Memorial Sloan Kettering Cancer Center
Johns Hopkins University; M.D. Anderson Cancer Center; Dana-Farber Cancer Institute and other collaborators

Active, not recruiting

Molecular Studies and Clinical Correlations in Human Prostatic Disease

Prostate Cancer

United States

Clinical Trials Sponsored by Artielle ImmunoTherapeutics

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations